{"name":"Viking Therapeutics, Inc.","slug":"viking-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VK2735","genericName":"VK2735","slug":"vk2735","indication":"Obesity or overweight with weight-related comorbidities","status":"phase_3"}]}],"pipeline":[{"name":"VK2735","genericName":"VK2735","slug":"vk2735","phase":"phase_3","mechanism":"VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters.","indications":["Obesity or overweight with weight-related comorbidities","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE56b2ktOVR0LWM1Y2ZKVUR4M2VMWG5VeTFvWWlScXlXbnh3ejZWS1JlVFJIWnZ1ekp4Z2xQeEhBNUlkZHB2cjBvQ1BzeG1LM0JEZnc?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance UK","summary":"Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history - Yahoo Finance UK","headline":"Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYmtFNjdGWXBNbkxfbGpBYW53RXhvSlRkb3FoVG5KazFjWEY4RWZuMjVtYWtWWjdmTmNhSHBrSGZmTi01S3R1QWVOWmU3Y2xuVk52bEtJSDZiWlQ2TXFBYy1qRlhJV3JScmtaMzR6aldMbXdGdmNMdEVfTmNTVkx6ZGJQeEZ3c2JwV1llVTEzb2lBOHpwUkFXczZ6RFh3ZW5JeTdaMUVmajIyWHhCbmlnRmQxbmFqdGljOWlVTDN5aE85RlE2b0o3Nw?oc=5","date":"2026-04-02","type":"deal","source":"Stocktwits","summary":"VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits","headline":"VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQSU9IZ0RPUndZNC0yNFhMdFUtYjZudzE3TkdmX09nbS1zSlhYY2FZdDhWRHpkbTU3RnpYQ3Jzb0FJU0NMdk5JdWJhX3JjUlgwYU5mTEN2MUNyalJqYVNVYmxBdXNFWkl4angzcVNSWUdpWDMydUVMNXhzUlNPTUlqMl94aEs1RWxOdExYM2ZSOWNpQTlZRFBaY3hoSk1kZ0dPWWp1TDN5TW0yTURQLWZONFFfaFo1SGlKcGcwaVlR?oc=5","date":"2026-03-19","type":"trial","source":"Seeking Alpha","summary":"Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha","headline":"Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZEg5R2VpX2RFU09Ld2R1b28zc1VUNnR4RmlmMThnN1FZNWwyTDZ2bW0xeTU0MWtqaExkaHdienFkOUFJUk5wN1JBYWhKS0Q5SnhmMDhqX2luUC1lLXVCV1JRdTRwSWQ5S2NOOWdia1p6YkRfUzF5VEZKdExfSGRfQzFyRm5FLXFNTktiZnY0eWRqUQ?oc=5","date":"2026-02-23","type":"pipeline","source":"The Motley Fool","summary":"3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - The Motley Fool","headline":"3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNOEN5dHR0TG04aGVkRkJhclNMSlRhVHpQMEQ4QzZkMDBpaG1CLWdTTkFkQW1BR2ZKSFJGVm1zMXlzZTAtX0VwcXZ0R1EzMEdIOTZDN2h1anNqZ3ZjcGc2SzVtNEFxemFqMjNia01hVm5MMUdWdzUwdHdLRENHcXBpMEZPQ3IteTlwTFBMS2NLXzU0RWN4RXc?oc=5","date":"2026-02-19","type":"pipeline","source":"The Motley Fool","summary":"Is Viking Therapeutics Stock Really Going to $125? - The Motley Fool","headline":"Is Viking Therapeutics Stock Really Going to $125?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOd3ZzNzZXWnZ3Wkg2LVB3Y2MydlRSODBEZ2V3c1FlWXRQbGRqRkRHSXBtME1MZ0ZfcFM3RzJLYWRudm14WC1BaER0Vkw3TnpIbzM5QjkyNEtSa2ZOTENrVEZ4enlkbEtsUWFkU2MxcUgwTkNhUzZ0TUgyUFRuN3gxb1J6cw?oc=5","date":"2026-02-14","type":"pipeline","source":"Seeking Alpha","summary":"Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX) - Seeking Alpha","headline":"Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOd0Ntakp5SnRIaWhDeGg5aXN6cGZsUkhTS2xZOGx2STdfYzNvZ3VuMnp3ekoySk9ROG9HRWpXai1WVkNMRUdFLU54elNnbGdsUWs0TW4xTGVqNUNyZEo2U0x3Zm56N3ZVMzdlUktGMEtZT3ZHam9waTRxY0FsSi1EM0dfN0ZnUW9HZHVVUG80Nzd5VXZ5R1I5c2RCV0pQNnBsUTY3eTNOb3pla244OUUyQUN2ZXB4VXdzX0JVcXhNVkhsUWVtWEU2UktXaU9fSGNXdUFKZlJqNFc1TlVHYmhEdkVkYjZrSjVjb3BvUG1hZ0dCaC1RdHA0VWJ6ZE4?oc=5","date":"2026-01-08","type":"trial","source":"PR Newswire","summary":"Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity - PR Newswire","headline":"Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOdHo3WWVzV21ucExRc0hYMlRXV3lRakhKcy1YM2dUWjdBMWhOSWhfUzJJS3lTM1JkOHJ6X1o5N1B0Wk1JdmRtTFlPR3llamRHS2NSUDdNMFNXdTZtbWJuTkhkTm5UV1F5UkVqdFFXZVM3eTJQbmVlNmpwRFVtY01kdm1uRUFQRWN2dFdFRUlVV0pMd0FkcU9yZWRR?oc=5","date":"2025-11-19","type":"deal","source":"Investor's Business Daily","summary":"Obesity Darling Undercuts A Buy Zone Despite A Speedy Win - Investor's Business Daily","headline":"Obesity Darling Undercuts A Buy Zone Despite A Speedy Win - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPSlNNLUtqTWRiMzVNY1hLakxSaTRVYjdjelJyWU9iY0R6cnBJRTdSQ2JJTi1iMHBFNm4yeUlwYk8zN2JiRUUwMEE4OUY5MkxYYVllQ2pqdVV5cEp4UlhJeTZBLTQ0R1FFY2hodEY5SGVyeXhVbHVfWWVqRjBlRzVtczBTZURuWDcyTFZfRVc0N092THFSMS1ET1VRZS1Gc0FSdV9wX3hkdUZpRGZkNnc?oc=5","date":"2025-11-10","type":"pipeline","source":"TipRanks","summary":"Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target? - TipRanks","headline":"Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORFBleUVFcmpXcV9Xekx6dWdhcUZxLTdybVlwWnBQV1huc3lRSVZLNF9tMFp4TGhXZUdrZ1FubUhaMXoyTjFxckVjeUtzR1Q0YnM4SEg4ZDFCbmhTYnNOOEZwdlJycTJsVUJyZ2Itd1JoSElMTko2MzFqWDd5M0o0WXNhQUh6eE1LUGc4?oc=5","date":"2025-11-03","type":"deal","source":"Yahoo Finance","summary":"Viking Therapeutics Could Be Pharma’s Next Big Buyout Target - Yahoo Finance","headline":"Viking Therapeutics Could Be Pharma’s Next Big Buyout Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxObDBPcXdsRW5LajlaVmpsUEtOaWgtODRfbnpveEJTa3ZoX25MSkthQm1pZHgzNWpIek13dUNYSlNkZEpUOXdUdlVEOHBZelZDZDRjM182VkVzajhQaW5EcURXbktqdGlVZ3BtVVJLcnhNRThRZUtsVmJQSEFTX0ZOZ1FybFY0dFlUVzIw?oc=5","date":"2025-10-09","type":"pipeline","source":"Yahoo Finance","summary":"Why Shares in Viking Therapeutics Surged This Week - Yahoo Finance","headline":"Why Shares in Viking Therapeutics Surged This Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5lcWI5NnNnOGRnTXVFVWxqMmNaNkR6cktGRk9fdzMwc3FOOFlmT09IbUVlaVFaVnFIMFk5dklKX0xQSWgxazUwREZ2eDI4b0hDTTllMFNHeW1tTERZdV9lMzZISWhDMm9FRVJrdEE0UDI4Ujl2dWd6UGtaM2xReEXSAYQBQVVfeXFMTm43RVU5S3RsMERhcTk1dGRjdERGTzVac0ZDMUR1S3piUkYzREd0Z0FVQ0RuWFJONXhLemlJa3kwZ1JSVTdxdG1kNE5PV3l0dDFyclcyNHl3SG1sYjJQaktrNktYQWRnYkM5V2x0TTlWTFdDUDVPY0JmTDgzQVRJcHRZUEZv?oc=5","date":"2025-08-19","type":"trial","source":"CNBC","summary":"Viking Therapeutics shares fall 40% on disappointing obesity pill trial data - CNBC","headline":"Viking Therapeutics shares fall 40% on disappointing obesity pill trial data","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}